DoD Lung Cancer, Idea Development Award | W81XWH 21 LCRP IDA

Opportunity Information: Apply for W81XWH 21 LCRP IDA

The DoD Lung Cancer Research Program (LCRP) Idea Development Award (FY21) is a Department of Defense funding opportunity designed to move bold, early-stage lung cancer ideas forward, especially those that are not yet fully mature but could open up new directions in the field. The program is specifically looking for conceptually innovative projects that carry real scientific risk but also offer the possibility of major payoff. The intent is to generate impactful data that can spark larger follow-on studies and ultimately speed progress toward reducing deaths and suffering from lung cancer. One clear boundary is that applications focused on mesothelioma are not allowed under this opportunity.

A central expectation of the award is that the proposed work is hypothesis-driven. Applicants are expected to present a well-formulated, testable hypothesis backed by a strong scientific rationale. Even though the mechanism supports early development, it is not meant for purely speculative ideas without grounding. To show that the approach is workable, preliminary data are required. Importantly, those supporting data do not have to come from lung cancer studies specifically, as long as they credibly demonstrate feasibility for the hypothesis and methods being proposed.

The award places heavy emphasis on two things: innovation and impact. Innovation, in this context, means more than incremental improvement. It can involve introducing a new paradigm, challenging an existing assumption in lung cancer biology or treatment, or reframing a persistent problem from a different perspective in a way that creates new possibilities. Impact is equally important and refers to the project’s potential to drive major advancements that measurably accelerate the broader goal of reducing lung cancer burden. Applicants are expected to clearly explain, in plain terms, what makes the work innovative and why it could matter in a significant way for lung cancer research and for patients, even if a direct clinical product is not expected by the end of the project. The opportunity explicitly notes that a proposal can be scientifically strong but still be considered a poor fit if it does not convincingly deliver on both innovation and high potential impact.

Another major feature is the strong encouragement of participation by New Investigators. The New Investigator category is meant for independent researchers who are still early in their careers, defined here as being within 10 years of their first faculty appointment or an equivalent position. New Investigators and Established Investigators are reviewed in separate tracks, which is intended to make the competition more balanced for early-career applicants. New Investigators are also strongly encouraged to include collaborations with researchers who have lung cancer expertise and/or other skills essential to the proposed project. The applicant is responsible for explaining how collaborators fill gaps and strengthen the overall team in a way that directly supports the research question. New Investigator applicants must meet specific eligibility requirements described in the program’s eligibility section.

From an administrative standpoint, this is a discretionary federal funding opportunity offered by the Department of Defense (Department of the Army, USAMRAA). The funding opportunity number is W81XWH 21 LCRP IDA, and the activity area is science and technology research and development (CFDA 12.420). The instrument types include grants and cooperative agreements, and eligibility is described as unrestricted, meaning many entity types may apply as long as they meet any stated conditions in the full announcement. The opportunity was posted March 8, 2021, had an original closing date of July 28, 2021, and anticipated making about 11 awards. The listing shows an award ceiling of 0, which typically indicates that the maximum amount is not stated in that summary field and would need to be confirmed in the full funding announcement.

Finally, proposals are expected to connect their significance to the Military Health System beneficiary population. Applicants should be explicit about relevance to service members, veterans, and other beneficiaries, and should articulate both the research value and the patient-centered importance of the expected outcomes. In short, the Idea Development Award is built for teams willing to take smart, defensible risks on fresh concepts, backed by enough preliminary evidence to be credible, and framed around a clear argument for why the work could meaningfully change the lung cancer landscape.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Lung Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 08, 2021.
• Applicants must submit their applications by Jul 28, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 11 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 LCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: